Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2000

View Archived Issues

Shire and D-Pharm reach agreement for development of DP-VPA for epilepsy

FDA issues action letter to Sonus for EchoGen

Seattle Genetics updates MAb program

Insmed and Taisho sign letter of intent for INS-1

The FDA grants orphan drug status for Avant's lead complement inhibitor

sNDA for Nolvadex in DCIS to undergo priority review

New findings could mean an end to a tragic illness

New dosing, formulations investigated for T-20

SangStat files NDA in Canada for Thymoglobulin

Palatin discontinues merger discussions with Molecular Biosystems

Antisoma takes up another product from ICRF for clinical development

Low-dose M-Vax shows promise in stage III metastatic melanoma

ImClone achieves milestone in IMC-C225 agreement with Merck KGaA

Amides synthesized at AstraZeneca useful for cytokine-mediated diseases

SB continues to search for novel anticonvulsants

Drugs for hyperlipidemia in development at Nippon Soda

Picower Institute presents new immunotherapeutic anticancer agents

Sigma-Tau prepares improved atypical antipsychotic agents

Anti-VEGF antisense oligonucleotides in the Aventis pipeline

News from ASCPT: Adolor presents positive clinical data on ADL-8-2698

Spiropentane nucleoside analogues designed and tested for antiviral activity

Clinical results supporting efficacy of newer generation COX-2 inhibitor presented at ASCPT

More MARISA results reported at ACC meeting by CV Therapeutics and collaborators

SmithKline Beecham's Avandia receives positive opinion from CPMP

Anticancer activity, pharmacokinetics and safety of E-7869

Impressive evidence for antiatherosclerotic efficacy of VasoCare therapy presented at ACC

Georgetown scientists describe mechanism of action of bertosamil

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...